-
Eisai Perampanel approved for 2 new indications
Time of Update: 2021-09-05
In September 2019, Perampanel was approved for marketing in China for the add-on treatment of patients with partial epilepsy (with or without secondary generalized seizures) aged 12 years and older .
-
Drug Administration: Nanchang Huayi's first batch of medical devices is being recalled
Time of Update: 2021-09-05
On August 19, the State Food and Drug Administration issued an announcement to notify Nanchang Huayi of its voluntary recall of some of its products in violation of regulations .
The company immediately initiated the recall procedure for this batch of products .
-
Beijing Food and Drug Administration Revises 63 Chinese Herbal Pieces Processing Regulations
Time of Update: 2021-09-05
On August 11, the Beijing Municipal Food and Drug Administration issued a notice on the public solicitation of opinions on the revised varieties (second batch) of the "Beijing Regulations for the Processing of Chinese Herbal Medicines" (2008 Edition) .
-
Shanghai Huilun "Serodosin" was approved for listing
Time of Update: 2021-09-05
A randomized, double-blind, placebo and positive drug controlled phase III clinical trial conducted by Japanese scholars included 457 BPH patients, divided into xerodoxine group (N=176) and tamsulosin group (N= 192) and placebo group (N=89), the results showed that xerodoxine improved the total IPSS score significantly better than placebo (P <0.
-
Rongchang Biotechnology is favored by American ADC giants!
Time of Update: 2021-09-05
Rongchang Bio-Vidicuzumab Research and Development ProgressIn the sci-tech innovation board prospectus, Rongchang Biological expects to complete the phase III confirmatory clinical trial of vedicitumumab for the treatment of gastric cancer in 2026, ensuring that it is fully approved for marketing .
-
Tigermed's application for listing of Vitorasheng injection is planned to be included in priority review
Time of Update: 2021-09-05
The proposed indication is: Duchenne whose dystrophin gene deletion experience shows that it can be treated by exon 53 skipping Muscular dystrophy .
For the treatment of Duchenne muscular dystrophy .
-
Roxastat, a targeted Nobel pathway, was approved by the European Commission for listing
Time of Update: 2021-09-05
Astellas Pharma and FibroGen today announced that the European Commission (EC) has approved the marketing of Evrenzo (roxadustat) for the treatment of adult patients with chronic kidney disease (CKD) related symptomatic anemia .
Retrieved 2021-08-20, from https:// releases/astellas-receives-european-commission-approval-for-first-in-class-evrenzo-roxadustat-for-adult-patients-with-symptomatic-anemia-of-chronic-kidney-disease-301359297.
-
Research progress in the development of long-acting technologies for protein and peptide drugs (Part 1)
Time of Update: 2021-09-05
To improve the stability of protein and peptide drugs, prolong the half-life in the body, and make it long-acting .
-
Ma Yinglong Pharmaceutical Appoints Liu Pingan as Deputy General Manager
Time of Update: 2021-09-05
On August 20, Ma Yinglong Pharmaceutical issued an announcement stating that the company held the twelfth meeting of the tenth board of directors on August 19 and passed the "Proposal on the Appointment of Senior Executives .
Liu Ping’an was appointed as the company’s deputy general manager .
-
Huabei Pharmaceutical's new rabies drug, omiltivizumab, has not been approved for large specifications
Time of Update: 2021-09-05
Article source: Medical Rubik's Cube InfoOn August 12, North China Pharmaceutical submitted a new class 1 recombinant human anti-rabies monoclonal antibody (ormutivimab) for the passive immunization of rabies virus-exposed patients.
-
Lymphoma Express: The first XPO1 inhibitor to treat r/r DLBCL; how is CAR-T treatment progress
Time of Update: 2021-09-05
SADAL research key data (source: NextMed database)OS subgroup analysis (Source: J Hematol Oncol)The results show that for patients with relapsed or refractory DLBCL who have previously received ≥2 lines of chemoimmunotherapy, the oral monotherapy Selinesor can induce sustained anti-tumor activity, and adverse reactions can be controlled .
-
Huabei Pharmaceutical: Withdrawal of registration application for recombinant human anti-rabies monoclonal antibody injection
Time of Update: 2021-09-05
Recently, based on research and analysis of clinical needs, market conditions, R&D costs and other factors, the subsidiary new drug company voluntarily withdrew the registration application of recombinant human anti-rabies monoclonal antibody injection 500 IU/2.
-
Li Hongjing, general manager, secretary of the board of directors, and director of Aojing Medical resigns
Time of Update: 2021-09-05
Li Hongjing has applied to resign from the position of director, general manager and secretary of the board of directors of the company.
Before appointing the new general manager and secretary of the board of directors, the chairman of the company, Mr.
-
Variant strains ravaging mRNA vaccines or spawning 470 billion years of sales market domestic layout of enterprises at a glance
Time of Update: 2021-09-05
mRNA new crown vaccine year "absorbs gold" or exceeds 470 billionmRNA new crown vaccine year "absorbs gold" or exceeds 470 billionAt present, the main R&D and sales companies of the global mRNA COVID-19 vaccine are:Moderna of the United States; Pfizer/Germany BioNTech (owns global market rights outside of Greater China); Fosun Pharma/Germany BioNTech (owns greater Emergency use authorization) .
-
Tasly Launches Phase III Study of Compound Danshen Dripping Pills in the Treatment of Acute Altitude Sickness in the United States
Time of Update: 2021-09-05
Article source: Medical Rubik's Cube InfoRecently, Tasly registered a Phase III clinical study on the prevention and treatment of acute altitude sickness (AMS) with T89 (Compound Danshen Dripping Pills) on the American Clinical Network .
-
Deqi Pharmaceuticals and De Ruizhi Pharmaceutical Co., Ltd. to Promote the Research and Development of Small Molecule Drugs for Difficult Drug Targets
Time of Update: 2021-09-05
On August 9, Deqi Pharmaceuticals and De Ruizhi Pharmaceuticals announced a cooperation to jointly promote the research and development of small molecule anti-tumor first-in-class drugs .
Up to now, De Rui Zhi Yao has made a contribution to the development of a pre-clinical drug candidate of De Qi Pharmaceutical .
-
Pharmaceutical stocks plummeted. Hengrui, Mindray, Changchun Hi-tech, WuXi and others staged a battle royale!
Time of Update: 2021-09-05
On the whole, this performance is as stable as ever, but because of careful comparison, the company's operating income and main business gross profit margin are not as good as market expectations, plus the investment indicator-Hillhouse Capital reduced its holdings in the second quarter Half of the shares are regarded as a major negative .
-
Two in a row!
Time of Update: 2021-09-05
According to the announcement of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration, the product was approved for clinical use in China this time, and it is planned to be developed for intravenous administration to treat patients with advanced solid tumors or lymphomas without effective treatment .
-
Candidates for licensed pharmacists can sign up
Time of Update: 2021-09-05
The examination is based on the 2021 pharmacist vocational qualification examination pharmacy management and regulations subject outline .
Attachment: 2021 national licensed pharmacist vocational qualification examination outline, pharmaceutical management and regulatory subject adjustment content
-
Pfizer's blockbuster smoking cessation drug Chantix ushered in imitation products threatened
Time of Update: 2021-09-05
Although Pfizer Chantix's competitor, Par Pharmaceuticals, received accelerated approval from the FDA, it is not surprising that Chantix lost its main patent protection in November last year .
In July of this year, Pfizer has voluntarily recalled 12 batches of the smoking cessation drug Chantix.
